A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy
Abstract
A splice site variation (c. 603-91G > A or rs3812718) in the SCN1A gene has been claimed to influence efficacy and dose requirements of carbamazepine and phenytoin. We investigated the relationship between c. 603-91G > A polymorphism and response to antiepileptic drugs (AEDs) in 482 patients with drug-resistant and 401 patients with drug-responsive focal epilepsy. Most commonly used AEDs were carbamazepine and oxcarbazepine. The distribution of c. 603-91G > A genotypes was similar among drug-resistant and drug-responsive subjects, both in the entire population and in the groups treated with carbamazepine or oxcarbazepine. There was no association between the c. 603-91G > A genotype and dosages of carbamazepine or oxcarbazepine. These findings rule out a major role of the SCN1A polymorphism as a determinant of AED responseKeywords
This publication has 11 references indexed in Scilit:
- The clinical impact of pharmacogenetics on the treatment of epilepsyEpilepsia, 2009
- Association between SCN1A polymorphism and carbamazepine‐resistant epilepsyBritish Journal of Clinical Pharmacology, 2008
- Nova2 Interacts with a Cis-Acting Polymorphism to Influence the Proportions of Drug-Responsive Splice Variants of SCN1AThe American Journal of Human Genetics, 2007
- A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dosePharmacogenetics and Genomics, 2006
- Update on pharmacogenetics in epilepsy: a brief reviewThe Lancet Neurology, 2006
- Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoinProceedings of the National Academy of Sciences, 2005
- A novel mechanism underlying drug resistance in chronic epilepsyAnnals of Neurology, 2003
- Parameters for reliable results in genetic association studies in common diseaseNature Genetics, 2002
- Pharmacoresistance in EpilepsyCNS Drugs, 1998
- Proposal for Revised Classification of Epilepsies and Epileptic SyndromesEpilepsia, 1989